Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 151: During treatment with rifampicin, some patients experience mild elevation in bilirubin with normal transaminases. What is the cause of this phenomenon?

A. Hemolysis
B. Transient cholestasis with bile duct injury
C. Microsomal enzyme induction
D. Hepatic adaptation (Correct Answer)

Explanation: **Explanation:** **1. Why "Hepatic Adaptation" is correct:** Rifampicin is a potent inducer of hepatic microsomal enzymes [1]. During the initial phase of therapy, it competes with bilirubin for uptake into hepatocytes and interferes with its excretion [3]. This leads to a mild, transient rise in serum bilirubin (predominantly unconjugated) without an increase in transaminases (ALT/AST). This phenomenon is termed **"Hepatic Adaptation."** It is a self-limiting process; as the liver adapts to the enzyme induction, bilirubin levels typically return to normal within a few weeks despite continued treatment. It does not signify hepatotoxicity and does not require discontinuation of the drug. **2. Why other options are incorrect:** * **A. Hemolysis:** While Rifampicin can rarely cause immune-mediated hemolytic anemia (usually during intermittent therapy) [2], it would be accompanied by a drop in hemoglobin and increased reticulocyte count, which is not the standard presentation of this biochemical shift. * **B. Transient cholestasis:** Cholestasis would typically involve an elevation in Alkaline Phosphatase (ALP) and Gamma-glutamyl transferase (GGT), along with potential bile duct injury markers, which are absent here. * **C. Microsomal enzyme induction:** While Rifampicin *is* a potent enzyme inducer [1], the induction itself is the *mechanism* leading to adaptation, but the clinical phenomenon of isolated bilirubin rise is specifically defined as "Hepatic Adaptation." **3. High-Yield Clinical Pearls for NEET-PG:** * **Rifampicin Toxicity:** The most common side effect is **hepatotoxicity** (more common when combined with Isoniazid) [1]. However, isolated hyperbilirubinemia is benign. * **Discoloration:** Warn patients about orange-red discoloration of urine, sweat, and tears (harmless). * **Flu-like syndrome:** Occurs with intermittent (twice weekly) dosing of Rifampicin [2]. * **Drug Interactions:** Due to CYP450 induction, Rifampicin decreases the efficacy of OCPs, Warfarin, and Sulfonylureas.

Question 152: What is the drug of choice for chronic hepatitis B?

A. Lamivudine (Correct Answer)
B. Interferon-alpha
C. Ribavirin
D. Zidovudine

Explanation: **Explanation:** **Correct Option: A (Lamivudine)** Lamivudine is a nucleoside analog that inhibits the Hepatitis B virus (HBV) DNA polymerase (reverse transcriptase). In the context of this specific question, Lamivudine is historically recognized as the first-line oral antiviral for chronic Hepatitis B due to its high efficacy in suppressing HBV DNA levels and its favorable safety profile compared to older therapies. While newer agents like Tenofovir and Entecavir are now preferred in modern guidelines due to lower resistance rates, Lamivudine remains the classic "textbook" answer for NEET-PG when listed among these specific options. **Incorrect Options:** * **B. Interferon-alpha:** While used in chronic HBV, it is administered via injection and carries a significant side-effect profile (flu-like symptoms, depression, bone marrow suppression), making it less preferred than oral antivirals for long-term management. * **C. Ribavirin:** This is used primarily for **Hepatitis C** (in combination with Interferon or DAAs) and has no significant clinical activity against Hepatitis B. * **D. Zidovudine (AZT):** This is a nucleoside reverse transcriptase inhibitor (NRTI) used exclusively for **HIV**; it does not have a role in treating Hepatitis B. **High-Yield Clinical Pearls for NEET-PG:** * **Current Gold Standard:** In clinical practice, **Tenofovir** or **Entecavir** are the drugs of choice due to a high genetic barrier to resistance. * **Resistance:** The major drawback of Lamivudine is the development of resistance (YMDD motif mutation). * **Pregnancy:** Tenofovir is the preferred agent to prevent mother-to-child transmission of HBV. * **Adefovir:** Another alternative, but limited by potential nephrotoxicity.

Question 153: Which of the following is the drug of choice for Campylobacter jejuni infection?

A. Azithromycin
B. Metronidazole
C. Ampicillin
D. Erythromycin (Correct Answer)

Explanation: **Explanation:** *Campylobacter jejuni* is one of the most common causes of bacterial gastroenteritis worldwide, typically presenting as inflammatory diarrhea (bloody stools), fever, and abdominal cramps. **1. Why Erythromycin is the Correct Answer:** Macrolides are the mainstay of treatment for *Campylobacter* enteritis. While many modern guidelines mention Azithromycin due to its convenient once-daily dosing, **Erythromycin** remains the classic "Drug of Choice" (DOC) cited in standard pharmacology textbooks (like K.D. Tripathi) and frequently tested in NEET-PG. It effectively shortens the duration of pathogen excretion and reduces the severity of symptoms if administered early. **2. Why Other Options are Incorrect:** * **Azithromycin (Option A):** While clinically effective and often preferred in practice due to better GI tolerance, Erythromycin is traditionally established as the gold standard in academic examinations for this specific organism. * **Metronidazole (Option B):** This is the DOC for anaerobic infections and protozoal diseases like Amoebiasis or Giardiasis. It has no activity against *Campylobacter*. * **Ampicillin (Option C):** *Campylobacter* species show high rates of resistance to penicillins; therefore, they are not used for empirical or definitive treatment. **3. High-Yield Clinical Pearls for NEET-PG:** * **Morphology:** *C. jejuni* is a Gram-negative, comma or S-shaped organism ("seagull wing" appearance) that is microaerophilic and grows best at 42°C (Skirrow’s medium). * **Complication:** It is the most common antecedent infection associated with **Guillain-Barré Syndrome (GBS)** due to molecular mimicry. * **Resistance Trend:** Fluoroquinolones (like Ciprofloxacin) were previously used but are now avoided due to rapidly rising resistance. * **Treatment Note:** Most cases are self-limiting and require only oral rehydration; antibiotics are reserved for severe or prolonged cases.

Question 154: Nalidixic acid is used in:

A. Urinary tract infections (UTI) (Correct Answer)
B. Bacillary dysentery
C. Enteric fever
D. Malaria

Explanation: **Explanation:** **Nalidixic acid** is the prototype of the first-generation **Quinolones**. Its clinical utility is primarily restricted to **Urinary Tract Infections (UTIs)** because it achieves high therapeutic concentrations in the urine but fails to reach effective systemic antibacterial levels in the blood or tissues. 1. **Why Option A is Correct:** Nalidixic acid is a narrow-spectrum urinary antiseptic. It is bactericidal against gram-negative organisms (like *E. coli, Proteus, Klebsiella*) by inhibiting the **DNA gyrase** enzyme. Following oral administration, it is rapidly absorbed but also rapidly excreted in the urine, making it effective for lower UTIs caused by susceptible strains. 2. **Why Other Options are Incorrect:** * **B & C (Bacillary Dysentery/Enteric Fever):** While Nalidixic acid has *in vitro* activity against some enteric pathogens, its poor systemic distribution and the rapid development of bacterial resistance make it unsuitable for systemic infections like typhoid (Enteric fever) or severe dysentery. Fluoroquinolones (e.g., Ciprofloxacin) are preferred for these conditions. * **D (Malaria):** Quinolones are antibacterial agents, not antimalarials. Malaria is caused by *Plasmodium* parasites and requires drugs like Chloroquine or Artemisinin-based combinations. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibits DNA gyrase (Topoisomerase II) in gram-negative bacteria. * **Resistance:** Resistance develops rapidly during treatment via chromosomal mutations (single-step mutation). * **Contraindication:** It should be avoided in patients with **G6PD deficiency** as it can precipitate hemolysis. * **Side Effects:** Common side effects include GI upset and CNS effects (headache, dizziness). It is generally avoided in children due to potential **cartilage toxicity** (a class effect of quinolones).

Question 155: What is the mechanism of action of maraviroc?

A. Cytochrome P450 inhibitor
B. GP 41 inhibitor
C. CCR5 inhibitor (Correct Answer)
D. GP 120 inhibitor

Explanation: Explanation: Mechanism of Action: Maraviroc is a unique antiretroviral agent classified as an Entry Inhibitor. For HIV to enter a host cell, the viral envelope protein gp120 must bind to the CD4 receptor and subsequently to a co-receptor, either CCR5 or CXCR4 [1]. Maraviroc selectively and reversibly binds to the CCR5 co-receptor on the surface of human CD4+ T-cells [1]. This binding induces a conformational change that prevents the viral gp120 from docking, thereby blocking the fusion and entry of "R5-tropic" HIV strains into the host cell [1], [4]. Analysis of Incorrect Options: * Option A (Cytochrome P450 inhibitor): While Maraviroc is a substrate of CYP3A4, it is not primarily used as an inhibitor [3]. Ritonavir is the classic example of a protease inhibitor used specifically for its CYP3A4 inhibitory effect ("boosting"). * Option B (GP 41 inhibitor): Enfuvirtide is the drug that targets gp41 [2]. It prevents the fusion of the viral envelope with the host cell membrane. * Option D (GP 120 inhibitor): Fostemsavir is a newer attachment inhibitor that binds directly to the viral gp120 protein to prevent initial attachment to CD4 cells. High-Yield Clinical Pearls for NEET-PG: * Tropism Testing: Before initiating Maraviroc, a Trofile assay must be performed. It is only effective against R5-tropic virus and is ineffective against X4-tropic or dual-tropic (R5X4) strains [1], [3]. * Metabolism: It is metabolized by CYP3A4; therefore, dosage adjustments are required when co-administered with CYP inhibitors (like protease inhibitors) or inducers (like Rifampin) [1], [3]. * Black Box Warning: Potential for hepatotoxicity which may be preceded by systemic allergic reactions (eosinophilia/rash) [3].

Question 156: What is the standard oral dose of oseltamivir for treatment?

A. 75 mg twice daily for 5 days orally (Correct Answer)
B. 75 mg twice daily for 5 days intravenously
C. 200 mg twice daily for 5 days orally
D. 200 mg twice daily for 5 days intravenously

Explanation: **Explanation:** **Oseltamivir** is a neuraminidase inhibitor used for the treatment and prophylaxis of Influenza A and B. It works by preventing the release of new viral particles from infected host cells. **1. Why Option A is Correct:** The standard therapeutic dose for adults and adolescents (weighing >40 kg) is **75 mg twice daily (BID) for 5 days**. For the drug to be most effective, it must be initiated within **48 hours** of the onset of symptoms. It is administered **orally** as a prodrug (oseltamivir phosphate), which is rapidly converted by hepatic esterases into its active form, oseltamivir carboxylate. **2. Why Other Options are Incorrect:** * **Options B & D:** Oseltamivir is specifically an **oral** medication. If intravenous neuraminidase inhibition is required (e.g., in critically ill patients unable to tolerate oral meds), **Peramivir** is the drug of choice. * **Option C:** 200 mg is not a standard dose. Higher doses (e.g., 150 mg BID) have been studied for severe infections (H5N1) or immunocompromised patients, but 75 mg BID remains the gold standard for seasonal influenza. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis Dose:** 75 mg **once daily** for 7–10 days (post-exposure) or up to 6 weeks (during community outbreaks). * **Mechanism:** Competitive inhibition of **Neuraminidase**, preventing viral shedding. * **Pregnancy:** Oseltamivir is the preferred antiviral for pregnant women with influenza. * **Side Effects:** Most common are GI upset (nausea/vomiting); rare but serious neuropsychiatric events (confusion, self-injury) have been reported in children. * **Zanamivir:** An alternative neuraminidase inhibitor administered via **inhalation** (contraindicated in asthma/COPD due to risk of bronchospasm).

Question 157: What is the most important side effect of Amphotericin B?

A. Fever and chills
B. Nephrotoxicity (Correct Answer)
C. Hyperkalemia
D. Anemia

Explanation: **Explanation:** **Amphotericin B** is a potent polyene antifungal used for systemic fungal infections. While it has several adverse effects, **Nephrotoxicity** is the most significant and dose-limiting side effect. **1. Why Nephrotoxicity is the Correct Answer:** Amphotericin B works by binding to ergosterol in fungal cell membranes to create pores. However, it also has a partial affinity for **cholesterol** in human renal tubular cells. This leads to: * **Direct Toxicity:** Damage to the renal tubular epithelium, causing electrolyte wasting (Type 1 RTA). * **Indirect Toxicity:** Vasoconstriction of the afferent arterioles, leading to decreased Renal Blood Flow (RBF) and Glomerular Filtration Rate (GFR). This "azotemia" occurs in nearly 80% of patients treated with the conventional deoxycholate form. **2. Analysis of Incorrect Options:** * **A. Fever and Chills:** These are common **infusion-related reactions** (the "shake and bake" phenomenon). While frequent, they are transient and manageable with premedication (NSAIDs/steroids), unlike the cumulative damage of nephrotoxicity. * **C. Hyperkalemia:** This is incorrect because Amphotericin B typically causes **Hypokalemia** and **Hypomagnesemia** due to increased distal tubular permeability and wasting. * **D. Anemia:** It causes a normocytic normochromic anemia due to decreased erythropoietin production by the damaged kidneys, but it is secondary to the renal impact. **High-Yield Clinical Pearls for NEET-PG:** * **Liposomal Amphotericin B:** Developed to reduce nephrotoxicity by targeting the drug specifically to fungal cells and avoiding the kidneys. * **Saline Loading:** Administering 1 liter of normal saline before the infusion is the standard clinical practice to minimize nephrotoxicity. * **Drug of Choice:** Despite its toxicity, it remains the gold standard for **Mucormycosis** and severe **Visceral Leishmaniasis**.

Question 158: Roxithromycin is:

A. A long acting macrolide (Correct Answer)
B. A short action quinolone
C. A short acting macrolide
D. A long acting polypeptide

Explanation: **Explanation:** **Roxithromycin** is a semi-synthetic **macrolide antibiotic** derived from Erythromycin. It is categorized as a **long-acting macrolide** primarily due to its superior pharmacokinetic profile compared to the prototype drug, Erythromycin. 1. **Why Option A is Correct:** Roxithromycin possesses a significantly longer elimination half-life (approx. **10–12 hours**) compared to Erythromycin (approx. 1.5 hours). This allows for convenient **twice-daily (BD) dosing**, improving patient compliance. It is more acid-stable, has better oral bioavailability, and achieves higher tissue concentrations. 2. **Why Other Options are Incorrect:** * **Option B & C:** Roxithromycin belongs to the macrolide class (characterized by a large lactone ring), not quinolones (e.g., Ciprofloxacin). It is considered "long-acting" relative to the older generation of macrolides. * **Option D:** Polypeptide antibiotics (e.g., Polymyxin B, Bacitracin) have a completely different chemical structure and mechanism of action (disrupting cell membranes). **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Like all macrolides, it inhibits bacterial protein synthesis by binding to the **50S ribosomal subunit**. * **Spectrum:** Similar to Erythromycin but more potent against *Legionella pneumophila*. * **Drug Interactions:** Roxithromycin has a **lower affinity for Cytochrome P450** enzymes compared to Erythromycin and Clarithromycin, resulting in fewer drug-drug interactions (e.g., with Theophylline or Warfarin). * **Clinical Use:** Commonly used for respiratory tract infections, ENT infections, and skin/soft tissue infections. * **Comparison:** While Roxithromycin is long-acting, **Azithromycin** remains the macrolide with the longest half-life (~68 hours), allowing for once-daily dosing.

Question 159: According to the recent classification of antitubercular drugs, which of the following drugs is classified under Group II?

A. Ethambutol
B. Streptomycin (Correct Answer)
C. Levofloxacin
D. Imipenem

Explanation: The classification of antitubercular drugs has been updated by the WHO to prioritize oral regimens and optimize the treatment of Drug-Resistant TB (DR-TB). **Explanation of the Correct Answer:** **Streptomycin** is classified under **Group II** (Second-line Injectable Agents). Historically, this group included Kanamycin, Capreomycin, and Amikacin. However, in the most recent WHO guidelines, Streptomycin remains the representative injectable for this category, though its use is declining in favor of all-oral regimens. **Analysis of Incorrect Options:** * **Ethambutol (Option A):** This is a **Group I** drug (First-line oral agents). Group I includes the primary "HRZE" regimen (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol). * **Levofloxacin (Option B):** This belongs to **Group A** (Fluoroquinolones) in the newer MDR-TB classification. Fluoroquinolones (Levofloxacin, Moxifloxacin) are now considered the most important components of MDR-TB treatment. * **Imipenem (Option D):** This is classified under **Group III** (or Group C in newer nomenclature), which consists of "Add-on agents" or "Other second-line agents" like Linezolid, Clofazimine, and Carbapenems. **NEET-PG High-Yield Pearls:** * **New WHO MDR-TB Classification:** * **Group A:** Fluoroquinolones (Levofloxacin, Moxifloxacin). * **Group B:** Second-line oral agents (Clofazimine, Cycloserine). * **Group C:** Add-on agents (Ethionamide, Linezolid, Bedaquiline, Delamanid). * **Bedaquiline:** Inhibits mycobacterial ATP synthase; it is a breakthrough drug for MDR-TB. * **Streptomycin Side Effect:** Ototoxicity (vestibular damage) and nephrotoxicity; it is contraindicated in pregnancy.

Question 160: Which of the following antibiotics can cause diabetes insipidus?

A. Chloramphenicol
B. Minocycline
C. Demeclocycline (Correct Answer)
D. Linezolid

Explanation: **Explanation:** **Demeclocycline** is a tetracycline derivative that acts as a specific antagonist to **Antidiuretic Hormone (ADH)** at the level of the renal collecting ducts. It inhibits the activation of adenylyl cyclase and the subsequent action of cAMP, rendering the kidneys unresponsive to ADH. This induced state of **nephrogenic diabetes insipidus** is actually utilized therapeutically to treat **SIADH** (Syndrome of Inappropriate ADH secretion)

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free